

Bo Abrahamsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3702981/publications.pdf>

Version: 2024-02-01

264
papers

14,615
citations

22153

59
h-index

23533

111
g-index

276
all docs

276
docs citations

276
times ranked

12489
citing authors

#	ARTICLE	IF	CITATIONS
1	One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. <i>Osteoporosis International</i> , 2022, 33, 123-137.	3.1	7
2	Osteoarthritis in osteogenesis imperfecta: A nationwide register-based cohort study. <i>Bone</i> , 2022, 154, 116222.	2.9	4
3	Fractures following pregnancy in Osteogenesis imperfecta – A self-controlled case series using Danish Health Registers. <i>Bone</i> , 2022, 154, 116177.	2.9	3
4	Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). <i>Osteoporosis International</i> , 2022, 33, 57-66.	3.1	10
5	The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study. <i>BMC Endocrine Disorders</i> , 2022, 22, 14.	2.2	3
6	Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review. <i>Calcified Tissue International</i> , 2022, 110, 641-648.	3.1	17
7	Regulation of bone mass in endocrine diseases including diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101614.	4.7	3
8	Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. <i>Osteoporosis International</i> , 2022, 33, 1579-1589.	3.1	3
9	Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and Tj ETQq1 1 0.784314.rgBT /Overlock 10	2.9	5
10	FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study. <i>Osteoporosis International</i> , 2022, , 1.	3.1	1
11	Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study. <i>Osteoporosis International</i> , 2022, 33, 2155-2164.	3.1	3
12	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. <i>Archives of Osteoporosis</i> , 2022, 17, .	2.4	13
13	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 264-281.	3.6	132
14	Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway. <i>Osteoporosis International</i> , 2021, 32, 1395-1404.	3.1	9
15	A comparison of fracture risk assessment tools. , 2021, , 1589-1609.		1
16	Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?. <i>Current Osteoporosis Reports</i> , 2021, 19, 182-188.	3.6	7
17	Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. <i>Health Technology Assessment</i> , 2021, 25, 1-106.	2.8	3
18	The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. <i>Osteoporosis International</i> , 2021, 32, 1961-1971.	3.1	13

#	ARTICLE	IF	CITATIONS
19	Epidemiology of Tumor-Induced Osteomalacia in Denmark. <i>Calcified Tissue International</i> , 2021, 109, 147-156.	3.1	18
20	A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. <i>Endocrine</i> , 2021, 73, 509-529.	2.3	15
21	Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. <i>JBMR Plus</i> , 2021, 5, e10522.	2.7	8
22	Validation of the Fracture Risk Evaluation Model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data. <i>Bone</i> , 2021, 147, 115934.	2.9	11
23	Assessing Health Consequences of Vitamin D Fortification Utilizing a Societal Experiment Design: Methodological Lessons Learned from the D-Tect Project. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8136.	2.6	2
24	Accelerated osteoarthritis in women with polycystic ovary syndrome: a prospective nationwide registry-based cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 225.	3.5	7
25	Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. <i>Journal of Bone and Mineral Research</i> , 2021, 36, 2162-2176.	2.8	5
26	Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A Danish national cohort study. <i>Bone</i> , 2021, 153, 116158.	2.9	0
27	Pre-fracture medication use as a predictor of 30-day mortality in hip fracture patients: an analysis of 141,201 patients. <i>HIP International</i> , 2020, 30, 101-106.	1.7	10
28	The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes. <i>Calcified Tissue International</i> , 2020, 106, 88-93.	3.1	4
29	Age at hip fracture and life expectancy in Denmark – Secular trends over two decades. <i>Bone</i> , 2020, 130, 115083.	2.9	12
30	Proton pump inhibitors and fracture risk. The HUNT study, Norway. <i>Osteoporosis International</i> , 2020, 31, 109-118.	3.1	16
31	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1682-1699.	3.6	53
32	Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3215-3225.	3.6	17
33	Nutrients, Diet, and Other Factors in Prenatal Life and Bone Health in Young Adults: A Systematic Review of Longitudinal Studies. <i>Nutrients</i> , 2020, 12, 2866.	4.1	9
34	Hiding in plain sight – unreported osteoporotic vertebral fractures. <i>European Radiology</i> , 2020, 30, 4711-4712.	4.5	1
35	Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom. <i>Osteoporosis International</i> , 2020, 31, 1535-1544.	3.1	31
36	Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. <i>Bone</i> , 2020, 134, 115296.	2.9	13

#	ARTICLE	IF	CITATIONS
37	Assessment of fracture risk in women with eating disorders: The utility of dual-energy x-ray absorptiometry (DXA)â€”Clinical cohort study. <i>International Journal of Eating Disorders</i> , 2020, 53, 595-605.	4.0	8
38	Oral Bisphosphonate Use and All-cause Mortality in Patients With Moderate-to-Severe (Grade 3-5) Chronic Kidney Disease: A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 894-900.	2.8	8
39	Fractures in women with eating disordersâ€”Incidence, predictive factors, and the impact of disease remission: Cohort study with background population controls. <i>International Journal of Eating Disorders</i> , 2020, 53, 1080-1087.	4.0	19
40	The association between renal function and BMD response to bisphosphonate treatment: Real-world cohort study using linked national registers. <i>Bone</i> , 2020, 137, 115371.	2.9	8
41	Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 24-40.	2.8	14
42	Response to Shao Et Al.. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 619-620.	2.8	0
43	Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 820-832.	2.8	46
44	OR13-03 Understanding Why Older People with Low Trauma Fractures Die Prematurely. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
45	Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1188-1199.	2.8	19
46	Osteoporosis; Prevention and Calcium-Vitamin D Treatment. , 2019, , 270-274.		0
47	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	3.1	69
48	Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2150-2158.	2.8	37
49	Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1727-1734.	2.9	21
50	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019, 30, 1733-1743.	3.1	38
51	Excess mortality following hip fracture in patients with diabetes according to age: a nationwide population-based cohort study of 154,047 hip fracture patients. <i>Age and Ageing</i> , 2019, 48, 559-563.	1.6	12
52	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019, 40, 333-368.	20.1	136
53	Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 34-39.	1.0	30
54	Long term time trends in use of medications associated with risk of developing osteoporosis: Nationwide data for Denmark from 1999 to 2016. <i>Bone</i> , 2019, 120, 94-100.	2.9	15

#	ARTICLE	IF	CITATIONS
55	Side effects of drugs for osteoporosis and metastatic bone disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1063-1071.	2.4	78
56	Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. <i>Bone</i> , 2019, 120, 476-481.	2.9	27
57	Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. <i>Thyroid</i> , 2019, 29, 332-340.	4.5	74
58	Vitamin D supplementation for musculoskeletal health outcomes in adults – The end of the beginning?. <i>Maturitas</i> , 2019, 122, 87-88.	2.4	3
59	Socioeconomic status in Danish women with polycystic ovary syndrome: A register-based cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 440-450.	2.8	10
60	Increased risk of thyroid disease in Danish women with polycystic ovary syndrome: a cohort study. <i>Endocrine Connections</i> , 2019, 8, 1405-1415.	1.9	18
61	Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. <i>European Journal of Endocrinology</i> , 2019, 180, 407-416.	3.7	52
62	Does bisphosphonate treatment reduce the risk of future cancer?. <i>Chinese Clinical Oncology</i> , 2019, 8, S3-S3.	1.2	1
63	Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study. <i>Thyroid</i> , 2018, 28, 566-574.	4.5	98
64	Response to Letter to the Editor: “Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 362-363.	3.6	5
65	Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. <i>Cardiovascular Diabetology</i> , 2018, 17, 37.	6.8	133
66	The Changing Role of Patient Education in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 761-762.	2.8	2
67	Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture – limitations and scope for fracture liaison services in prevention of hip fracture. <i>Osteoporosis International</i> , 2018, 29, 109-114.	3.1	19
68	Lactose avoidance and bone. <i>Maturitas</i> , 2018, 109, A1-A2.	2.4	3
69	Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 278.	0.8	8
70	High calcium intake in men not women is associated with all-cause mortality risk: Melbourne Collaborative Cohort Study. <i>Archives of Osteoporosis</i> , 2018, 13, 101.	2.4	6
71	Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. <i>Osteoporosis International</i> , 2018, 29, 1875-1885.	3.1	14
72	Social inequality and fractures – secular trends in the Danish population: a case-control study. <i>Osteoporosis International</i> , 2018, 29, 2243-2250.	3.1	20

#	ARTICLE	IF	CITATIONS
73	A New Fracture Risk Assessment Tool (FREM) Based on Public Health Registries. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1967-1979.	2.8	34
74	Diagnosis and management of bone fragility in diabetes: an emerging challenge. <i>Osteoporosis International</i> , 2018, 29, 2585-2596.	3.1	237
75	Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3205-3214.	3.6	61
76	Risk factors for post peak bone loss and osteoporotic fracture: Lessons from population studies. , 2018, , 123-152.		0
77	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017, 28, 767-774.	3.1	113
78	Hyperkalemia is Associated with Increased 30-Day Mortality in Hip Fracture Patients. <i>Calcified Tissue International</i> , 2017, 101, 9-16.	3.1	18
79	Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects. <i>Osteoporosis International</i> , 2017, 28, 139-149.	3.1	60
80	Prenatal exposure to vitamin D from fortified margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the D-TECT observational study. <i>British Journal of Nutrition</i> , 2017, 117, 872-881.	2.3	6
81	The calcium and vitamin D controversy. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 107-114.	2.7	23
82	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. <i>Osteoporosis International</i> , 2017, 28, 2023-2034.	3.1	126
83	Reply to: systematic review and meta-analysis for the association of bone mineral density and osteoporosis/osteopenia with vascular calcification in women. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 2144-2145.	1.9	0
84	Neonatal vitamin D status from archived dried blood spots and future risk of fractures in childhood: results from the D-TECT study, a population-based case-cohort study. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 155-161.	4.7	24
85	Bespoke or one size fits all? Vitamin D fortification, targeted supplementation in risk groups or individual measurement?. <i>Maturitas</i> , 2017, 103, 1-2.	2.4	3
86	The emperor redressed: treating osteoporosis to prevent hip fractures in the oldest old. <i>Journal of Internal Medicine</i> , 2017, 282, 560-562.	6.0	2
87	Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2301-2309.	3.6	78
88	Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3848-3857.	3.6	144
89	Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study. <i>Osteoporosis International</i> , 2017, 28, 2573-2581.	3.1	23
90	Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors. <i>European Geriatric Medicine</i> , 2017, 8, 408-412.	2.8	2

#	ARTICLE	IF	CITATIONS
91	Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. <i>BMC Women's Health</i> , 2017, 17, 17.	2.0	20
92	Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. <i>Osteoporosis International</i> , 2017, 28, 2921-2928.	3.1	27
93	Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. <i>Osteoporosis International</i> , 2017, 28, 2935-2944.	3.1	31
94	Epidemiology of Fractures in Diabetes. <i>Calcified Tissue International</i> , 2017, 100, 109-121.	3.1	51
95	Mechanisms of diabetes mellitus-induced bone fragility. <i>Nature Reviews Endocrinology</i> , 2017, 13, 208-219.	9.6	678
96	Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 125-134.	2.8	89
97	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017, 55, 195-201.	1.3	4
98	The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. <i>Rhinology</i> , 2017, 55, 195-201.	1.3	12
99	Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion. <i>Calcified Tissue International</i> , 2016, 99, 243-249.	3.1	29
100	Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. <i>International Journal of Cardiology</i> , 2016, 225, 250-257.	1.7	32
101	Maternal serum retinol and β -carotene concentrations and neonatal bone mineralization: results from the Southampton Women's Survey cohort. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 1183-1188.	4.7	20
102	Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 2159-2166.	2.8	84
103	Diagnostic devices for osteoporosis in the general population: A systematic review. <i>Bone</i> , 2016, 92, 58-69.	2.9	35
104	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. <i>BMJ</i> , The, 2016, 353, i3365.	6.0	73
105	Proton pump inhibitors and osteoporosis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 420-425.	4.3	68
106	Risk of fracture in adults on renal replacement therapy: a Danish national cohort study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1654-1662.	0.7	59
107	Low Levels of Hemoglobin at Admission Are Associated With Increased 30-Day Mortality in Patients With Hip Fracture. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2016, 7, 115-120.	1.4	23
108	Temporal trends in the use of antithrombotics at admission. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2016, 87, 368-373.	3.3	14

#	ARTICLE	IF	CITATIONS
109	Hyponatremia and hypernatremia are associated with increased 30-day mortality in hip fracture patients. <i>Osteoporosis International</i> , 2016, 27, 397-404.	3.1	36
110	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 234-244.	2.8	16
111	Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 709-717.	2.8	32
112	Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population—Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 488-490.	2.8	6
113	Risks and Benefits of Bisphosphonate Therapies. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 20-28.	2.6	108
114	The epidemiology of fractures in Denmark in 2011. <i>Osteoporosis International</i> , 2016, 27, 2017-2025.	3.1	39
115	Use of anti-osteoporotic drugs in central Norway after a forearm fracture. <i>Archives of Osteoporosis</i> , 2015, 10, 235.	2.4	12
116	Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1553-1559.	2.8	23
117	Vitamin D insufficiency is associated with increased risk of first-trimester miscarriage in the Odense Child Cohort. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 633-638.	4.7	78
118	Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2015, 172, 627-638.	3.7	115
119	Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. <i>Osteoporosis International</i> , 2015, 26, 513-519.	3.1	48
120	A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1335-1342.	3.6	105
121	Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study. <i>Archives of Osteoporosis</i> , 2015, 10, 36.	2.4	22
122	Nutrient and food intakes in early life and risk of childhood fractures: a systematic review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1182-1195.	4.7	43
123	Sequential osteoporosis treatment—the order of things. <i>Nature Reviews Endocrinology</i> , 2015, 11, 570-572.	9.6	2
124	The Excess Risk of Major Osteoporotic Fractures in Hypothyroidism Is Driven by Cumulative Hyperthyroid as Opposed to Hypothyroid Time: An Observational Register-Based Time-Resolved Cohort Analysis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 898-905.	2.8	71
125	Epidemiology of forearm fractures in adults in Denmark: national age- and gender-specific incidence rates, ratio of forearm to hip fractures, and extent of surgical fracture repair in inpatients and outpatients. <i>Osteoporosis International</i> , 2015, 26, 67-76.	3.1	31
126	Denosumab: A novel antiresorptive drug for osteoporosis. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, 105-114.	1.3	12

#	ARTICLE	IF	CITATIONS
127	Duration of Thyroid Dysfunction Correlates with All-Cause Mortality. The OPENTHYRO Register Cohort. <i>PLoS ONE</i> , 2014, 9, e110437.	2.5	57
128	Low Serum Thyrotropin Level and Duration of Suppression as a Predictor of Major Osteoporotic Fractures—The OPENTHYRO Register Cohort. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2040-2050.	2.8	96
129	Women's experiences of their osteoporosis diagnosis at the time of diagnosis and 6 months later: A phenomenological hermeneutic study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2014, 9, 22438.	1.6	29
130	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1123-1129.	0.9	26
131	Response: Is heart failure a debatable end-point for bisphosphonate treatment in an older osteoporotic population?. <i>Journal of Internal Medicine</i> , 2014, 275, 198-198.	6.0	0
132	Oral Bisphosphonate Use and Total Knee/Hip Implant Survival: Validation of Results in an External Population-Based Cohort. <i>Arthritis and Rheumatology</i> , 2014, 66, 3233-3240.	5.6	39
133	Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy. <i>Scandinavian Journal of Urology</i> , 2014, 48, 350-355.	1.0	8
134	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1-23.	2.8	1,424
135	Safety issues with bisphosphonate therapy for osteoporosis. <i>Rheumatology</i> , 2014, 53, 19-31.	1.9	122
136	Status of drug development for the prevention and treatment of osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 245-253.	5.0	17
137	Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. <i>Osteoporosis International</i> , 2014, 25, 757-762.	3.1	64
138	Comment on Tadrous et al.: Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. <i>Osteoporosis International</i> , 2014, 25, 2669-2669.	3.1	1
139	A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. <i>BoneKEy Reports</i> , 2014, 3, 574.	2.7	43
140	Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases. <i>Osteoporosis International</i> , 2013, 24, 2639-2647.	3.1	28
141	Anti-osteoporotic therapy in Denmark—predictors and demographics of poor refill compliance and poor persistence. <i>Osteoporosis International</i> , 2013, 24, 2079-2097.	3.1	32
142	Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids. <i>Osteoporosis International</i> , 2013, 24, 1891-1897.	3.1	5
143	Bisphosphonates and colon cancer: reply. <i>Osteoporosis International</i> , 2013, 24, 1141-1142.	3.1	0
144	The influence of early exposure to vitamin D for development of diseases later in life. <i>BMC Public Health</i> , 2013, 13, 515.	2.9	25

#	ARTICLE	IF	CITATIONS
145	The bisphosphonates: risks and benefits of long term use. <i>Current Opinion in Pharmacology</i> , 2013, 13, 435-439.	3.5	20
146	Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study. <i>Clinical Endocrinology</i> , 2013, 79, 333-341.	2.4	70
147	Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: Cohort analysis using a national prescription database. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 455-463.	2.8	32
148	Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database. <i>Osteoporosis International</i> , 2013, 24, 369-372.	3.1	10
149	Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. <i>Osteoporosis International</i> , 2013, 24, 245-252.	3.1	59
150	Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. <i>Osteoporosis International</i> , 2013, 24, 321-328.	3.1	22
151	Proton pump inhibitor use and fracture risk — effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. <i>Bone</i> , 2013, 57, 269-271.	2.9	35
152	Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. <i>Bone</i> , 2013, 56, 16-22.	2.9	91
153	Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1701-1717.	2.8	150
154	The role of vitamin D supplementation in patients with rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2013, 9, 411-422.	8.0	17
155	Central nervous system medications and falls risk in men aged 60-75 years: the Study on Male Osteoporosis and Aging (SOMA). <i>Age and Ageing</i> , 2013, 42, 121-124.	1.6	25
156	Heart failure in patients treated with bisphosphonates. <i>Journal of Internal Medicine</i> , 2013, 274, 342-350.	6.0	20
157	Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. <i>BMJ</i> , The, 2013, 346, f1514-f1514.	6.0	0
158	Eliminating the need for fasting with oral administration of bisphosphonates. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 395.	2.0	47
159	Osteoporosis and vertebral fractures in men aged 60–74 years. <i>Age and Ageing</i> , 2012, 41, 171-177.	1.6	41
160	Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study. <i>Osteoporosis International</i> , 2012, 23, 2693-2701.	3.1	77
161	Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. <i>Osteoporosis International</i> , 2012, 23, 2873-2884.	3.1	25
162	Essentials in rheumatology: disease management * I34. Metabolic bone diseases. <i>Rheumatology</i> , 2012, 51, iii7-iii13.	1.9	0

#	ARTICLE	IF	CITATIONS
163	Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. <i>Bone</i> , 2012, 50, 1196-1200.	2.9	27
164	Characteristics of patients who suffer major osteoporotic fractures despite adhering to bisphosphonate treatment: A national prescription register study. <i>Bone</i> , 2012, 50, S58.	2.9	0
165	Antidepressant medications and osteoporosis. <i>Bone</i> , 2012, 51, 606-613.	2.9	144
166	A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3161-3169.	3.6	179
167	Season of Birth and the Risk of Hip Fracture in Danish Men and Women Aged 65+. <i>Frontiers in Endocrinology</i> , 2012, 3, 2.	3.5	14
168	Esophageal and gastric cancer incidence and mortality in alendronate users. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 679-686.	2.8	57
169	Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1405-1412.	2.8	56
170	Atypical femur fractures: Refining the clinical picture. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 975-976.	2.8	15
171	Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2670-2681.	3.6	186
172	Disentangling the Emerging Evidence around Atypical Fractures. <i>Current Rheumatology Reports</i> , 2012, 14, 212-216.	4.7	7
173	Risk factors for fracture in elderly men: a population-based prospective study. <i>Osteoporosis International</i> , 2012, 23, 521-531.	3.1	23
174	Pattern of use of DXA scans in men: a cross-sectional, population-based study. <i>Osteoporosis International</i> , 2012, 23, 183-191.	3.1	12
175	FRAX® in clinical practice. <i>Nature Reviews Rheumatology</i> , 2011, 7, 686-688.	8.0	5
176	Safety of bisphosphonates. <i>Bone</i> , 2011, 49, 103-110.	2.9	135
177	Bone freezing and bisphosphonates. <i>Maturitas</i> , 2011, 69, 1-2.	2.4	1
178	Effects of COL1A1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk. <i>Osteoporosis International</i> , 2011, 22, 1145-1156.	3.1	14
179	Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study. <i>Osteoporosis International</i> , 2011, 22, 1401-1409.	3.1	35
180	Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. <i>Osteoporosis International</i> , 2011, 22, 1493-1501.	3.1	28

#	ARTICLE	IF	CITATIONS
181	Do calcium plus vitamin D supplements increase cardiovascular risk?. BMJ: British Medical Journal, 2011, 342, d2080-d2080.	2.3	43
182	Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. Evidence-Based Medicine, 2011, 16, 168-169.	0.6	9
183	Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates. Scandinavian Journal of Public Health, 2011, 39, 312-318.	2.3	15
184	Inverse Association Between Duration of Use of Acid-Suppressive Medications and Fracture Risk—Reply. Archives of Internal Medicine, 2011, 171, 1044.	3.8	0
185	Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate. Archives of Internal Medicine, 2011, 171, 998-1004.	3.8	76
186	Bisphosphonate adverse effects, lessons from large databases. Current Opinion in Rheumatology, 2010, 22, 404-409.	4.3	60
187	Adverse Effects of Bisphosphonates. Calcified Tissue International, 2010, 86, 421-435.	3.1	139
188	Adiponectin and Peak Bone Mass in Men: A Cross-Sectional, Population-Based Study. Calcified Tissue International, 2010, 87, 36-43.	3.1	10
189	Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. Osteoporosis International, 2010, 21, 373-380.	3.1	137
190	Validation of a 5-year risk score of hip fracture in postmenopausal women. The Danish Nurse Cohort Study. Osteoporosis International, 2010, 21, 2135-2142.	3.1	9
191	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2010, 25, 2267-2294.	2.8	994
192	Vitamin D status and PTH in young men: a cross-sectional study on associations with bone mineral density, body composition and glucose metabolism. Clinical Endocrinology, 2010, 73, 573-580.	2.4	51
193	Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age and Ageing, 2010, 39, 203-209.	1.6	428
194	Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ: British Medical Journal, 2010, 340, b5463-b5463.	2.3	342
195	Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5258-5265.	3.6	147
196	Time trends for alendronate prescription practices in patients with chronic pulmonary disease and patients exposed to systemic glucocorticoids. Bone, 2010, 47, S195.	2.9	0
197	More on Reports of Esophageal Cancer with Oral Bisphosphonate Use. New England Journal of Medicine, 2009, 360, 1789-1792.	27.0	79
198	No Association Between Hip Geometry and Four Common Polymorphisms Associated with Fracture: The Danish Osteoporosis Prevention Study. Calcified Tissue International, 2009, 84, 276-285.	3.1	14

#	ARTICLE	IF	CITATIONS
199	Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. <i>Osteoporosis International</i> , 2009, 20, 299-307.	3.1	71
200	Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. <i>Osteoporosis International</i> , 2009, 20, 585-597.	3.1	33
201	Excess mortality following hip fracture: a systematic epidemiological review. <i>Osteoporosis International</i> , 2009, 20, 1633-1650.	3.1	805
202	Atrial fibrillation in fracture patients treated with oral bisphosphonates. <i>Journal of Internal Medicine</i> , 2009, 265, 581-592.	6.0	102
203	Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1095-1102.	2.8	316
204	FEV1 for identification of low BMD in patients with COPD. <i>Bone</i> , 2009, 44, S373-S374.	2.9	0
205	Performance of BMD-independent risk scores adapted from the WHI and FRAX(R) collaborations in prediction of 5-year risk of hip fracture: The Danish nurses cohort. <i>Bone</i> , 2009, 44, S397.	2.9	1
206	Prevention and treatment of osteoporosis in women: an update. <i>Obstetrics, Gynaecology and Reproductive Medicine</i> , 2009, 19, 157-163.	0.3	3
207	Changes in bone mineral density (BMD) around the cemented Exeter stem: A prospective study in 18 women with 5 years follow-up. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2008, 79, 494-498.	3.3	20
208	Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 555-567.	1.5	92
209	Clinical importance of accuracy-error and reference values in DXA—a nationwide study. <i>Journal of Clinical Densitometry</i> , 2007, 10, S209.	1.2	0
210	Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1465-E1473.	3.5	35
211	Fracture risk in Danish men with prostate cancer: a nationwide register study. <i>BJU International</i> , 2007, 100, 749-754.	2.5	73
212	Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. <i>Clinical Endocrinology</i> , 2007, 67, 897-903.	2.4	14
213	Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Peak Bone Mass in Non-sedentary Men: Results from the Odense Androgen Study. <i>Calcified Tissue International</i> , 2007, 81, 421-429.	3.1	30
214	Comment on Schott et al.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. <i>Osteoporosis International</i> , 2007, 18, 699-699.	3.1	0
215	Estimates of fracture probability in Denmark: reply to Johansson et al. <i>Osteoporosis International</i> , 2007, 18, 1145-1146.	3.1	1
216	Population-based reference values for bone mineral density in young men. <i>Osteoporosis International</i> , 2007, 18, 1507-1514.	3.1	43

#	ARTICLE	IF	CITATIONS
217	Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. <i>Thrombosis and Haemostasis</i> , 2007, 97, 234-239.	3.4	7
218	MTHFR c.677C>T polymorphism as an independent predictor of peak bone mass in Danish men—results from the Odense Androgen Study. <i>Bone</i> , 2006, 38, 215-219.	2.9	37
219	Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. <i>Bone</i> , 2006, 39, 189-198.	2.9	27
220	Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS). <i>Thrombosis and Haemostasis</i> , 2006, 95, 915-916.	3.4	4
221	Ten-Year Absolute Risk of Osteoporotic Fractures According to BMD T Score at Menopause: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 796-800.	2.8	49
222	Ten-year prediction of osteoporosis from baseline bone mineral density: development of prognostic thresholds in healthy postmenopausal women. The Danish Osteoporosis Prevention Study. <i>Osteoporosis International</i> , 2006, 17, 245-251.	3.1	17
223	Ten year absolute risk of osteoporotic fractures according to BMD T-score at menopause. The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2006, .	2.8	0
224	Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures. <i>Calcified Tissue International</i> , 2005, 76, 90-97.	3.1	60
225	Performance of four clinical screening tools to select peri- and early postmenopausal women for dual X-ray absorptiometry. <i>Osteoporosis International</i> , 2005, 16, 764-772.	3.1	29
226	Geometry of the proximal femur in relation to age and sex: a cross-sectional study in healthy adult danes. <i>Acta Radiologica</i> , 2005, 46, 514-518.	1.1	33
227	Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. <i>BMJ: British Medical Journal</i> , 2005, 330, 818.	2.3	44
228	Prevention and treatment of osteoporosis in women. <i>Current Obstetrics & Gynaecology</i> , 2005, 15, 251-258.	0.2	10
229	Are effects of MTHFR (C677T) genotype on BMD confined to women with low folate and riboflavin intake? Analysis of food records from the Danish osteoporosis prevention study. <i>Bone</i> , 2005, 36, 577-583.	2.9	57
230	Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins. <i>Bone</i> , 2005, 36, 727-735.	2.9	43
231	Technology evaluation: denosumab, Amgen. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 604-10.	2.8	9
232	Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. <i>European Journal of Endocrinology</i> , 2004, 150, 671-679.	3.7	19
233	Two Single Nucleotide Polymorphisms in the CYP17 and COMT Genes—Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women with or without Hormone Replacement Therapy. <i>Calcified Tissue International</i> , 2004, 75, 123-132.	3.1	29
234	Skeletal changes in osteoprotegerin and receptor activator of nuclear factor- κ B ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. <i>Bone</i> , 2004, 35, 256-265.	2.9	53

#	ARTICLE	IF	CITATIONS
235	Response rates to oestrogen treatment in perimenopausal women: 5-year data from The Danish Osteoporosis Prevention Study (DOPS). <i>Maturitas</i> , 2004, 48, 307-320.	2.4	6
236	Hormone Replacement Therapy Dissociates Fat Mass and Bone Mass, and Tends to Reduce Weight Gain in Early Postmenopausal Women: A Randomized Controlled 5-Year Clinical Trial of the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 333-342.	2.8	99
237	A Common Methylenetetrahydrofolate Reductase (C677T) Polymorphism Is Associated With Low Bone Mineral Density and Increased Fracture Incidence After Menopause: Longitudinal Data From the Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 723-729.	2.8	92
238	Effects of the Natural and Artificial Menstrual Cycle on the Production of Osteoprotegerin and the Bone Resorptive Cytokines IL-1b and IL-6. <i>Calcified Tissue International</i> , 2003, 72, 18-23.	3.1	19
239	Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism. <i>Calcified Tissue International</i> , 2003, 73, 210-216.	3.1	32
240	Polymorphisms in the CYP19 and AR Genes?Relation to Bone Mass and Longitudinal Bone Changes in Postmenopausal Women With or Without Hormone Replacement Therapy: The Danish Osteoporosis Prevention Study. <i>Calcified Tissue International</i> , 2003, 74, 25-34.	3.1	48
241	Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1208-1214.	3.8	32
242	Standardization of BMD T-Scores in the First Five Years After the Menopause. <i>Journal of Clinical Densitometry</i> , 2003, 6, 87-95.	1.2	3
243	Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: A randomized controlled study. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 33-39.	1.3	60
244	Association of a Common Allelic Polymorphism (C677T) in the Methylene Tetrahydrofolate Reductase Gene with a Reduced Risk of Osteoporotic Fractures. A Case Control Study in Danish Postmenopausal Women. <i>Calcified Tissue International</i> , 2002, 71, 386-392.	3.1	60
245	Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. <i>Clinical Endocrinology</i> , 2002, 57, 273-281.	2.4	23
246	When Should Densitometry Be Repeated in Healthy Peri- and Postmenopausal Women: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 2061-2067.	2.8	15
247	Two Polymorphisms in the Vitamin D Receptor Gene-Association With Bone Mass and 5-Year Change in Bone Mass With or Without Hormone-Replacement Therapy in Postmenopausal Women: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1535-1544.	2.8	26
248	Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. <i>Maturitas</i> , 2001, 40, 211-220.	2.4	34
249	Discordance Between Changes in Bone Mineral Density Measured at Different Skeletal Sites in Perimenopausal Women-Implications for Assessment of Bone Loss and Response to Therapy: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1212-1219.	2.8	43
250	Correlations between insulin sensitivity and bone mineral density in non-diabetic men. <i>Diabetic Medicine</i> , 2000, 17, 124-129.	2.3	97
251	Cytokines and Bone Loss in a 5-Year Longitudinal Study-Hormone Replacement Therapy Suppresses Serum Soluble Interleukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 1545-1554.	2.8	88
252	Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. <i>Maturitas</i> , 2000, 36, 181-193.	2.4	139

#	ARTICLE	IF	CITATIONS
253	Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. <i>Bone</i> , 2000, 26, 137-145.	2.9	32
254	Vitamin D Receptor Alleles Do Not Predict Bone Mineral Density or Bone Loss in Danish Perimenopausal Women. <i>Bone</i> , 1998, 22, 571-575.	2.9	46
255	Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded?. <i>British Journal of Radiology</i> , 1998, 71, 934-943.	2.2	42
256	Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. <i>Bone</i> , 1997, 20, 251-258.	2.9	41
257	Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. <i>Maturitas</i> , 1997, 28, 137-145.	2.4	55
258	Site of Osteodensitometry in Perimenopausal Women: Correlation and Limits of Agreement Between Anatomic Regions. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1471-1479.	2.8	72
259	Impact of hemodialysis on dual X-ray absorptiometry, bioelectrical impedance measurements, and anthropometry. <i>American Journal of Clinical Nutrition</i> , 1996, 63, 80-86.	4.7	91
260	Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. <i>Bone</i> , 1995, 16, 385-390.	2.9	154
261	Relevance of Ki-67 expression in the classification of non-Hodgkin's lymphomas: a morphometric and double-immunostaining study. <i>Histopathology</i> , 1992, 20, 13-20.	2.9	13
262	Age at first major osteoporotic fracture in Danes aged 50 and over: influence of diabetes on mean age at fracture and 1 year mortality. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
263	Osteoporosis epidemiology using international cohorts. <i>Current Opinion in Rheumatology</i> , 0, Publish Ahead of Print, .	4.3	1
264	Population screening for fracture risk in postmenopausal women – a logical step in reducing the osteoporotic fracture burden?. <i>Osteoporosis International</i> , 0, , .	3.1	2